RLYB

Rallybio Corp

Healthcare Biotechnology

Portfolio

Watchlist

15.56 USD -0.19 ( 1.21%)

Last update at 2026-11-09T15:17:00Z

VOLUME

15195

Market Cap

66.32M

Momentum Score

…

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range

15.53

Low

16.00

High

52 Week Price Range

1.23

Low

9.14

High

Momentum Score

…

Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

AI Summary

Rallybio Corp is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and serious genetic conditions. Long-term growth may be driven by pipeline clinical-trial progress, potential regulatory approvals or orphan-designation pathways, and partnerships or licensing that could expand development resources, which may appeal to investors seeking exposure to rare-disease therapeutics.
Key investment risks include high clinical and regulatory uncertainty, likely ongoing cash burn with recurrent financing needs, and limited commercial revenue until any candidate achieves approval.

Risk Score

High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close

15.75

Dividend Yield

Revenue TTM

0.00M

Revenue Per Share

Gross Profit TTM

0.00M

Debt / Equity

0.00

ROE

-62.43%

Net Debt

-24.10M

ROCE

-63.83%

Diluted EPS TTM

-1.88

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Income before tax	-65.58M	-45.51M	-24.94M	-17.46M
Net income	-66.49M	-47.01M	-24.93M	-17.63M
Selling general administrative	27.20M	18.74M	7.67M	6.28M
Reconciled depreciation	0.17M	0.11M	0.06M	0.03M
Ebit	-67.88M	-45.65M	-25.30M	-17.64M
Ebitda	-65.58M	-45.50M	-24.83M	-17.39M
Depreciation and amortization	2.31M	0.15M	0.47M	0.25M
Non operating income net other	1.02M	-1.35M	-	-
Operating income	-67.88M	-45.65M	-25.30M	-17.64M
Other operating expenses	67.88M	45.65M	25.30M	17.64M
Interest expense	2.31M	0.01M	0.05M	0.04M
Tax provision	-	0.00M	-0.01M	0.00M
Interest income	1.96M	0.05M	0.17M	0.20M
Net interest income	1.96M	0.04M	0.12M	0.16M
Income tax expense	0.91M	1.50M	-0.01M	0.17M
Total revenue	0.00M	0.00M	0.00M	0.00M
Total operating expenses	67.88M	45.65M	25.30M	17.64M
Total other income expense net	2.31M	0.14M	0.36M	0.18M
Net income from continuing ops	-65.58M	-45.51M	-26.45M	-17.56M
Net income applicable to common shares	-66.65M	-45.51M	-26.45M	-17.56M

Breakdown	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total assets	115.62M	180.44M	182.19M	141.86M	21.61M
Other current assets	4.86M	1.05M	5.54M	1.03M	1.46M
Total liab	9.44M	11.12M	6.58M	187.88M	41.89M
Total stockholder equity	106.18M	169.32M	175.60M	-47.01M	-20.57M
Other current liab	8.07M	9.45M	5.95M	4.26M	2.95M
Common stock	0.00M	0.00M	0.00M	0.45M	0.23M
Capital stock	0.00M	0.00M	0.00M	-	-
Retained earnings	-235.25M	-160.68M	-94.03M	-47.01M	-20.57M
Other liab	-	-	0.03M	0.01M	0.94M
Other assets	-	-	182.19M	-	-
Cash	24.49M	56.96M	175.33M	140.23M	19.46M
Total current liabilities	9.26M	10.74M	6.55M	5.84M	3.81M
Net debt	-24.10M	-56.40M	-175.33M	-140.23M	-19.46M
Short term debt	0.22M	0.18M	-	-	-
Short long term debt total	0.39M	0.56M	-	-	-
Other stockholder equity	341.41M	330.21M	269.63M	47.01M	20.57M
Property plant equipment	-	0.39M	0.51M	0.29M	0.20M
Total current assets	114.79M	179.50M	180.87M	141.26M	20.92M
Long term investments	0.24M	0.03M	0.81M	0.31M	0.49M
Net tangible assets	-	169.32M	175.60M	-46.02M	-20.28M
Short term investments	85.44M	112.04M	-	-	-
Accounts payable	0.98M	1.11M	0.60M	1.58M	0.86M
Accumulated other comprehensive income	0.01M	-0.21M	-	-	-
Common stock total equity	-	0.00M	0.00M	-	-
Retained earnings total equity	-	-160.68M	-94.03M	-	-
Non currrent assets other	0.24M	0.03M	0.81M	-	-
Non current assets total	0.83M	0.94M	1.32M	0.60M	0.69M
Capital lease obligations	0.39M	0.56M	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Investments	-112.12M	-2.00M	-1.94M	-1.94M
Change to liabilities	3.71M	0.73M	0.72M	0.73M
Total cashflows from investing activities	-112.17M	-2.33M	-2.07M	-0.19M
Total cash from financing activities	51.08M	82.97M	144.89M	31.57M
Change to operating activities	-1.42M	-2.80M	1.40M	1.34M
Net income	-66.65M	-47.01M	-26.45M	-17.56M
Change in cash	-118.38M	35.10M	120.78M	16.35M
Begin period cash flow	175.33M	140.23M	19.46M	3.10M
End period cash flow	56.96M	175.33M	140.23M	19.46M
Total cash from operating activities	-57.28M	-45.53M	-22.04M	-15.03M
Issuance of capital stock	51.53M	86.20M	145.21M	31.60M
Depreciation	0.17M	0.11M	0.06M	0.03M
Sale purchase of stock	0.22M	82.97M	-	-
Other cashflows from financing activities	-0.67M	-3.23M	-0.32M	-0.03M
Change to netincome	10.57M	3.65M	2.23M	0.44M
Capital expenditures	0.05M	0.33M	0.14M	0.19M
Cash flows other operating	-4.64M	-3.00M	-	-
Cash and cash equivalents changes	-118.38M	35.10M	-	-
Change in working capital	-0.94M	-3.78M	2.12M	2.07M
Stock based compensation	9.50M	3.65M	0.70M	0.19M
Other non cash items	0.64M	1.50M	1.52M	0.14M
Free cash flow	-57.34M	-45.87M	-22.18M	-15.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
RLYB Rallybio Corp	-0.19 1.21%	15.56	-	-	-	0.83	-1.41
NVO Novo Nordisk A/S	0.47 1.18%	40.78	41.58	31.15	2.13	32.99	4.70
VRTX Vertex Pharmaceuticals Inc	1.49 0.27%	548.58	30.22	24.27	10.36	6.50	24.66
REGN Regeneron Pharmaceuticals Inc	8.76 0.97%	913.11	29.07	20.12	7.57	3.82	19.42
ARGNF argenx SE	- -%	900.30	45.77	31.25	13.84	7.12	36.06

Profile*

Rallybio Corp

Address

234 Church Street, New Haven, CT, United States, 06510

Contact

203 859 3820

Website

https://www.rallybio.com

Employees

Name	Title	Year Born
Dr. Martin W. MacKay Ph.D.	Co-Founder, CEO & Chairman	1956
Dr. Stephen Uden M.B, M.D.	Co- Founder, Pres, COO & Chief Scientific Officer	1958
Mr. Jeffrey M. Fryer CPA	Co-Founder, CFO & Treasurer	1970
Ms. Ami Bavishi	Head of Investor Relations & Corp. Communications	NA
Dr. Steven W. Ryder F.A.C.P, M.D.	Chief Medical Officer	1951
Dr. Martin W. MacKay Ph.D.	Co-Founder & Executive Chairman	1956
Dr. Stephen Uden M.B, M.D.	Co-Founder, President, CEO & Director	1958
Mr. Jonathan I. Lieber M.B.A.	CFO & Treasurer	1970
Ms. Ami Bavishi	Head of Investor Relations & Corporate Communications	NA
Dr. Steven W. Ryder F.A.C.P, M.D.	Chief Medical Officer	1952

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

Top Gainers*
Top Losers*

Equity Sectors*

Basic Materials

-1.70%
Communication Services

+0.33%
Consumer Cyclical

+0.45%
Consumer Defensive

-0.56%
Energy

-0.25%
Financial Services

+0.49%
Healthcare

+0.20%
Industrials

+0.74%
Real Estate

+1.71%
Technology

-2.81%
Utilities

+0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

TYT	GBX 3102.38 +3.03%
CPG	GBX 33.81 -1.11%
DGED	GBX 93.25 -1.26%
LTOD	GBX 37.75 -1.44%
KNM	GBX 24500.00 +2.04%

DAR	GBX 8.30 +23.42%
VTY	GBX 276.20 +8.23%
GTCO	GBX 0.09 +6.98%
GLV	GBX 2.34 +6.36%
BUR	GBX 249.20 +5.95%

TMI	GBX 0.72 -6.49%
HSBA	GBX 1291.40 -5.42%
RKT	GBX 5218.00 -4.85%
TGA	GBX 643.00 -4.03%
RKH	GBX 61.70 -3.89%